HOME >> BIOLOGY >> NEWS
Wistar-developed antibody shows promise against brain tumors in Drexel trial

PHILADELPHIA - A new treatment procedure for high-grade cancers of the brain, one of the most aggressive and deadliest forms of cancer, has shown promise in extending the survival time of patients participating in a clinical trial conducted under the supervision of Luther W. Brady, M.D., the Hylda Cohn/American Cancer Society Professor of Clinical Oncology at Drexel University College of Medicine. The trial was performed in collaboration with The Wistar Institute in Philadelphia.

The findings, published in the December issue of the American Journal of Clinical Oncology, are the results of the first 10 years of an ongoing study begun in 1987. The study follows 180 patients who, following surgery and radiation therapy for their brain tumors, received injections of MAb425, a radioiodinated monoclonal antibody developed at The Wistar Institute. All of the patients were followed for five years or longer.

"These results clearly indicate a dramatic step forward in the treatment of brain tumors," says Brady.

Typically, patients with lower-grade gliomas, or brain tumors, die within 18 to 24 months, according to Brady. Patients with glioblastomas, a more aggressive form of tumor, usually die within 12 to 18 months. Of the 180 patients receiving the MAb425 injections, three patients with high-grade tumors were alive after five years and longer. Of the patients with the less aggressive tumor, eight were alive after five years and longer, and 50 percent of those patients were alive after 56 months.

"It's gratifying to see an antibody discovered in a Wistar laboratory showing such promise in the clinic against difficult-to-treat brain tumors," says Russel E. Kaufman, M.D., director and CEO of The Wistar Institute. "The process of translating basic discoveries into new therapies is often a lengthy and challenging one, but the reward can be profound - the ability to offer longer, healthier lives to patients."

The scientists who develo
'"/>

Contact: Franklin Hoke
hoke@wistar.upenn.edu
215-898-3716
The Wistar Institute
16-Dec-2002


Page: 1 2

Related biology news :

1. Wistar-discovered antibody will help diagnose appendicitis
2. Experimental hantavirus vaccine elicits strong antibody response in primates
3. Towards an AIDS vaccine: unusual antibody that targets HIV described by scientists at TSRI
4. Structure of HIV-neutralizing antibody solved
5. New antibody library speeds search for new detection tools
6. FDA approves new treatment, Campath , humanized monoclonal antibody, for patients with B-cell chronic lymphocytic leukemia
7. Rockefeller University researchers discover immune-cell mechanism that boosts therapeutic antibody potency
8. Abgenix to become sole owner of Xenomouse fully human antibody technology
9. Abgenix and CuraGen establish large-scale drug development alliance, companies to develop genomics-based human antibody drugs
10. Human Genome Sciences and Abgenix enter a broad collaboration to create fully human antibody therapeutics
11. Abgenix and Chiron enter Xenomouse Technology Collaboration, targets antibody products for autoimmune disease and cancer

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/11/2020)... OLDSMAR, Fla. (PRWEB) , ... June 08, 2020 ... ... increased demand for masks and other protective measures to protect workers in the ... doctors and their dedicated staffs who valiantly risk their lives every day to ...
(Date:6/5/2020)... Calif. (PRWEB) , ... June 04, 2020 , ... ... has filed a new patent application for simplified sample preparation for Next Generation ... that will greatly reduce cost, time, and complexity of sample preparation. , “I have ...
(Date:6/5/2020)... ... ... Greffex, a pioneering vaccine and gene therapy company based in Houston, Texas, ... for a global perspective to make an impact in a post pandemic world,” said ... an independent, director of the company. , “The Greffex board is excited to have ...
Breaking Biology News(10 mins):
(Date:7/18/2020)... MILWAUKEE (PRWEB) , ... July 16, 2020 , ... “We ... at Third Wave Bioactives. “It’s the only technology of its kind on the market ... flavor of onions with the protective capacity of traditional cultured ingredients, creating a natural ...
(Date:7/10/2020)... , ... July 08, 2020 , ... ... and products, announces a significant expansion of laboratory operations through its COVID-19 ... agencies implementing testing programs. , Bode-CARES provides a turnkey solution ...
(Date:7/10/2020)... ... 2020 , ... Sentien Biotechnologies, Inc., a clinical-stage biotechnology company ... Nissenson, M.D., F.A.C.P., as its Chief Medical Officer. Dr. Nissenson will join ... Dr. Nissenson serves as an Emeritus Professor of Medicine at the David ...
(Date:7/1/2020)... N.C. (PRWEB) , ... June 29, 2020 , ... ... reported year to date growth of 40% in 2020, despite many obstacles created ... technology, MedShift aims to increase revenue for its partnered medical practices and medical ...
Breaking Biology Technology:
Cached News: